CHARLESTON, S.C., Feb. 7 /PRNewswire/ -- JSJ Pharmaceuticals today announced a multi-year agreement under which it has assumed from Valeant Pharmaceuticals International the sales, marketing, and educational responsibilities for Oxsoralen-Ultra(R) (Methoxsalen capsules, USP, 10mg), 8-MOP(R) Capsules (Methoxsalen capsules, USP 10mg), and Oxsoralen Lotion 1% (Methoxsalen, USP, 1%). Oxsoralen-Ultra(R) is an important product for the treatment of severe, recalcitrant, disabling psoriasis which is not adequately responsive to other forms of therapy.
"This partnership with Valeant Pharmaceuticals represents a great opportunity for JSJ Pharmaceuticals to continue providing clinicians with the 'toolbox' of products for the management of clinical challenges faced on a daily basis in their practices and continues to provide patients suffering from recalcitrant psoriasis with treatment options for relief from this debilitating disease," said JSJ's Chief Operating Officer, Jonathan Alba.
About Psoriasis disease:
Psoriasis is an inflammatory skin condition and frequently is associated with "plaques" which appear as patches of raised, reddish skin covered by silvery-white scale. The skin often itches, and may crack and bleed which usually causes discomfort. Psoriasis is a lifelong skin disease during which patients experience periods of flares and remissions. As many as 7.5 millions Americans have psoriasis according to the National Institutes of Health, and approximately 150,000 new cases are diagnosed each year according to the American Academy of Dermatology.
JSJ Pharmaceuticals is a growing specialty pharmaceutical company focused on the development and commercialization of prescriptive products to meet the diverse needs of patients suffering from a wide range of dermatological conditions. More information can be found about JSJ Pharmaceuticals at www.jsjpharm.com.
Important Safety Information
Methoxsalen with UV radiation should be used only by physicians who have special competence in the diagnosis and treatment of psoriasis and who have special training and experience in photochemotherapy. The use of Psoralen and ultraviolet radiation therapy should be under constant supervision of such a physician. For the treatment of patients with psoriasis, photochemotherapy should be restricted to patients with severe, recalcitrant, disabling psoriasis which is not adequately responsive to other forms of therapy, and only when the diagnosis is certain. Because of the possibilities of ocular damage, aging of the skin, and skin cancer (including melanoma), the patient should be fully informed by the physician of the risks inherent in this therapy.
CAUTION: Oxsoralen-Ultra(R) (Methoxsalen Soft Gelatin Capsules) should not be used interchangeably with regular Oxsoralen(R) or 8-MOP(R) (Methoxsalen Hard Gelatin Capsules). This new dosage form of methoxsalen exhibits significantly greater bioavailability and earlier photosensitization onset time than previous methoxsalen dosage forms. Patients should be treated in accordance with the dosimetry specifically recommended for this product. The minimum phototoxic dose (MPD) and phototoxic peak time after drug administration prior to onset of photochemotherapy with this dosage form should be determined.